These studies demonstrated considerable and consistent antitumor efficacy for cabozantinib in tRCC patients, particularly those with TFE3 gene translocations. The gene discussed is TFE3; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.